LY3325656

DESCRIPTION

LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.

DETAILS

Cas: 1998714-25-2
Purity: 98%
Smiles: CC1=C(N(C)C=N1)C=2NC(=NN2)[C@@H]3C[C@H](N(C(=O)C4=CC(C(F)(F)F)=CC=C4)C)CCO3
Category: Compound
Molecular Weight: 448.44
Molecular Formula: C21H23F3N6O2

Lead Time: 4 - 5 weeks